A Table of Radionuclide-based Products Marketed in the US
Radionuclide therapeutic products are primarily used as parts of outpatient treatments in the United States. Though the list of FDA approved radionuclide therapeutic products is limited, research identified the following five products available in the U.S.: Xenon Xe 133, Lymphoseek, Cardiolite, Xofigo, and Metastron. These products have been arranged in a table in this spreadsheet.
In order to identify these products, we researched the existing therapies based on radionuclides in the United States. Upon finding the names of these products, we performed an extensive search of the patents, company websites and the National Institutes of Health (NIH) site to arrive at information on inventor and administration channel.
Xenon xe 133
Xenon Xe 133 is a gas, administered by inhalation used for evaluation and imaging studies targeting the pulmonary system and cerebral flow. The drug is administered as an outpatient treatment, with patients exhaling the gas through a single breath upon completion of their studies.
The drug is currently licensed to, and sold by, Lantheus Holdings, Inc. It was invented by Donald Ray Van Deripe, intended to be used in cancer treatments.
Lymphoseek, also known as Technetium Tc-99m tilmanocept, is primarily used as a radioactive agent, used to help mark lymph nodes during diagnostic and surgical procedures. It is injected into the patient after being diluted in 0.9% sodium chloride shortly before use.
Lymphoseek is currently sold by Cardinal Health, after having acquired licensing rights from inventors at Navidea Biopharmaceuticals, Inc.
Another outpatient imaging product, Cardiolite - also known as Sodium Pertechnetate Tc99m - is administered intravenously. It is primarily used for detecting myocardial abnormalities, evaluating function and identifying coronary disease.
Cardiolite is currently licensed and sold by Lantheus Medical Holdings. It was originally invented by Alan Davidson and Alun Jones.
The radionuclide therapeutic, Xofigo consists of radium Ra 223 dichloride. It is primarily used as a treatment for prostate cancer which is recurrent after surgical interventions. Xofigo is administered through injection every 4-6 weeks.
Currently, Xofigo is currently licensed and sold by Bayer Health but was invented by Roy Larson.
Metastron is a radionuclide treatment used in cases of metastatic bone cancer. The active agent is Strontium Chloride, SR-89, and
is administered to outpatients intravenously.
Metastron was also invented by Roy Larson. The drug is now licensed and sold by GE Healthcare.
There are few radionuclide therapies in the U.S. A majority of these therapies - including Xenon Ze 133, Lymphoseek and Cardiolite - are used as diagnostic agents, supporting imaging studies to detect abnormalities. Another few, Metastron and Xofigo, are primarily used in the treatment of cancers.